---
run_id: halo-evidence-vs-diagnosis-validation-v7-substrate-workflow-07
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: substrate_workflow
run_number: 7
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 703
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 86235e082879e8119f7adb956d7b870675e03f798daf72f80f32353376157508
condition_packet_sha256: 86235e082879e8119f7adb956d7b870675e03f798daf72f80f32353376157508
output_file: model-outputs/substrate_workflow-07.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 07)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `substrate_workflow`, run 7 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 703, on the frozen condition packet.

## Output

**Recommendation**
Recommend that the CEO commit to the **targeted evidence pass**.

**Reasoning**
The current "upbeat story" is constructed from vanity metrics and cognitive biases rather than validated learning. You must caution the CEO that the company is currently operating under a "halo effect" (BK-0048-card-001): the recent bump in net revenue retention has led leadership to re-describe the team as "customer-obsessed" and "disciplined," whereas the exact same behaviors were labeled "too bespoke" and "reactive" six months ago. The traits have not changed; only the performance signal has.

Furthermore, the evidence for "success" is contaminated. The revenue growth is largely artificial (72% tied to discounts), and the customer quotes are primed (collected after telling customers the feature was a top priority). According to the principles of validated learning (BK-0007-card-001), real progress is measured by empirical customer behavior, not by shipping features or hitting execution targets. The behavior data is alarming: only 31% of front-line reviewers return after the first week, and the product is being abandoned in regulated insurance queues due to a lack of auditor-explainability.

Scaling now (Option 1) would be a mistake because it lacks a "strategy kernel" (BK-0001-card-001). It is a list of coherent actions (hires, quota expansion) without a valid diagnosis. The current "diagnosis"—that Review Assist is a market wedge—is based on halo-tinted data. Narrowing the focus to regulated compliance (Option 3) is premature, as it pivots the company based on a single failure point before the broader utility of the tool is actually validated. The evidence pass is the only option that treats the current situation as a hypothesis to be tested rather than a victory to be scaled.

**Strongest Reason Against**
The primary risk is **political and temporal**. The board locks the budget in twelve days. A recommendation to "pause" discounts and run a rigorous evidence pass may be perceived by the CEO and Sales leadership as a lack of momentum or an attempt to "stifle" a winning streak. In a high-pressure environment, choosing a "learning" phase over a "scaling" phase can be interpreted as a lack of confidence, potentially risking the budget allocation for the very resources needed to conduct the evidence pass.

**Observable Evidence That Would Change My Mind**
I would shift my recommendation to "Scale" if you can produce data showing that **front-line reviewer retention (currently 31%) has increased significantly in a cohort of customers who did NOT receive the six-month discount or the "top priority" sales pitch.** If the product's utility is driving retention independently of financial incentives and narrative priming, the "market wedge" diagnosis is validated, and the risk of scaling is drastically reduced.
